Opus Genetics Reports Q3 Earnings Miss on Lower Revenue and Negative EPS
Opus Genetics (IRD) reported third-quarter financial results that fell significantly short of market expectations. The company posted a GAAP earnings per share (EPS) of -$0.46, missing estimates by $0.31, while revenue totaled only $1.14 million, representing a 63% year-over-year decline and missing consensus by $0.94 million. Despite the earnings miss, management highlighted a strong cash position with an expected runway extending into 2029. This liquidity is intended to support upcoming clinical inflection points and potential opportunities regarding Priority Review Vouchers. The stock saw a slight downward movement in after-hours trading following the announcement.
Topics: cash runway earnings miss financial results revenue decline
Read the full article at Seeking Alpha
Part of the story Opus Genetics Reports Q3 Earnings Miss on Lower Revenue and Negative EPS (3 articles)